GlassScriptPhysician profile
Angela Floyd
NPI 1841733045
$6,673.57
in general payments reported to CMS, 2019-2025
26 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $245 · 2023: $2,593 · 2024: $2,318 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,428.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,259.49 | 2022-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $824.64 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $593.75 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $547.08 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lexicon Pharmaceuticals, INC. | $528.24 | 2023-2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $443.03 | 2023-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $439.06 | 2022-2024 | Verquvo |
| Pfizer INC. | $405.44 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $326.35 | 2022-2025 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $237.37 | 2023-2025 | Lifevest |
| Medtronic, INC. | $156.68 | 2024 | Reveal Linq |
| Janssen Pharmaceuticals, INC | $127.02 | 2023-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $122.36 | 2023-2024 | |
| Scpharmaceuticals INC. | $90.00 | 2024 | |
| Abbott Laboratories | $86.62 | 2022-2023 | Cardiomems |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $85.91 | 2022 | |
| Kestra Medical Technology Services, INC. | $73.91 | 2024-2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $72.29 | 2023-2025 | Nexletol |
| Lilly USA, LLC | $56.09 | 2023-2025 | Zepbound, Jardiance, Mounjaro |
| Alnylam Pharmaceuticals INC. | $38.67 | 2025 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $34.39 | 2024 | Arcalyst |
| Cleerly, INC. | $34.16 | 2024-2025 | Cleerly Labs, Cleerly Ischemia |
| Edwards Lifesciences Corporation | $33.47 | 2023 | Sapien 3 Ultra Resilia |
| Azurity Pharmaceuticals, INC. | $19.92 | 2024 | Edarbi |
| Bayer Healthcare Pharmaceuticals INC. | $19.05 | 2025 | |
| Boston Scientific Corporation | $18.58 | 2025 | Cds - Mct/Cem Monitoring |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Floyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.